2022 World Conference on Lung Cancer (ePosters)-EP08.01-089. Efficacy and Safety of Immune Checkpoint Inhibitors in Treating Brain Metastases in Patients With Non-small Cell Lung Cancer

EP08.01-089. Efficacy and Safety of Immune Checkpoint Inhibitors in Treating Brain Metastases in Patients With Non-small Cell Lung Cancer

Back to course

Pdf Summary

This study aimed to investigate the efficacy and safety of immune checkpoint inhibitors (ICIs) in treating brain metastases (BM) in patients with non-small cell lung cancer (NSCLC). The clinical data of 16 patients with BM of NSCLC who were treated with ICIs from April 2019 to April 2021 were analyzed. The patients underwent at least two cycles of ICI therapy, with MRI scans performed before and after each cycle for evaluation of treatment efficacy. <br /><br />Among the patients, 50% had a single brain metastasis and 50% had multiple BM. Four patients exhibited symptoms related to BM. Five patients underwent brain radiotherapy, with three of them being pretreated with ICIs. <br /><br />The results showed that all patients included in the study had stage IV NSCLC, with a majority of 87.5% being male. The median progression-free survival (mPFS) was 24.17 months, and the median overall survival (mOS) was not achieved. <br /><br />In terms of treatment efficacy, among the nine patients evaluated, three had a partial response (33.3%), one had advanced progressive disease (6.25%), and five had stable disease (31.25%). ICIs demonstrated a high intracranial control rate and prolonged mPFS in patients with BM of NSCLC. <br /><br />Overall, this study suggests that ICIs can be effective and safe in treating brain metastases in patients with NSCLC. It highlights the importance of incorporating ICIs into the treatment regimen for NSCLC patients with BM to achieve better outcomes.

Asset Subtitle

Fei Teng

Meta Tag

Speaker Fei Teng

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

immune checkpoint inhibitors

brain metastases

non-small cell lung cancer

clinical data

treatment efficacy

MRI scans

brain radiotherapy

stage IV NSCLC

progression-free survival

overall survival